• Tiamulin: Veterinary Research Workflows

  2026-09-09

  Tiamulin (Thiamutilin) combines strain-focused antibacterial activity with investigational anti-inflammatory effects, making it useful for integrated pathogen, cell-signaling, and PK/PD studies. This workflow shows how to formulate, dose, measure, and troubleshoot the compound while avoiding clinically important ionophore interactions.

• AZD3463: A Translational Blueprint for ALK Inhibition

  2026-09-09

  AZD3463 offers a strategic model for translating dual ALK/IGF1R inhibition into genotype-aware neuroblastoma research, with evidence spanning pathway suppression, apoptosis, chemotherapy sensitization, and orthotopic xenografts.

• γH2AX: From DNA Damage Signal to Translation

  2026-09-08

  A thought-leadership guide to using γH2AX as a mechanistic and translational readout in radiation oncology, with practical guidance for evaluating EGCG nanoparticle-enhanced FLASH-RT and selecting a robust immunofluorescence workflow.

• Relative vs Fractional Viability in Cancer Drug Testing

  2026-09-08

  Hannah R. Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer activity. By separating growth inhibition from cell killing and considering their different timing, the work provides a more informative framework for interpreting in vitro drug-response experiments.

• 25-Hydroxycholesterol Reprograms TAM Immunity

  2026-09-07

  Xiao et al. identify CH25H and lysosome-accumulated 25-hydroxycholesterol as an immunometabolic checkpoint that activates AMPKα and reinforces STAT6-dependent ARG1 production in tumor-associated macrophages. The study connects oxysterol compartmentalization with macrophage-mediated immune suppression and shows that targeting CH25H can improve antitumor immunity, including responses to anti-PD-1 therapy.

• Topotecan HCl Workflow for Cancer Assays

  2026-09-07

  Build more informative cancer-drug assays with Topotecan HCl by separating growth inhibition from actual cell killing. This workflow connects concentration and exposure schedules with orthogonal readouts for lung, breast, and prostate cancer models while highlighting practical formulation and troubleshooting decisions.

• Epigenetic Immune Signatures in Melanoma

  2026-09-05

  Anichini et al. compared five epigenetic drug classes and found that guadecitabine most consistently activated immune-related transcriptional programs in melanoma, including innate TLR, NF-κB, and interferon-associated pathways. The study links tumor-cell epigenetic remodeling with patient biopsy responses and provides a framework for selecting epigenetic partners for immune checkpoint blockade.

• BQCA and the Next Logic of M1 Signaling

  2026-09-04

  Benzyl Quinolone Carboxylic Acid (BQCA) offers a strategic way to study M1 muscarinic receptor signaling as a tunable, pathway-dependent process rather than a simple on/off response. This thought-leadership analysis connects BQCA’s pharmacology with GRK-regulated signaling bias, translational study design, and decision-making in cognitive and Alzheimer’s disease research.

• HyperFluor™ 594 Goat Anti-Rabbit IgG (H+L) Antibody

  2026-09-04

  Build clearer fluorescence workflows for neuroblastoma nanocarrier studies with a spectrally defined goat anti-rabbit IgG secondary antibody. This guide connects immunocytochemistry, tissue imaging, flow cytometry, and ELISA readouts to the iRGD-modified red blood cell membrane photodynamic therapy model.

• Topotecan HCl and DNA Damage Burden

  2026-09-03

  Topotecan HCl is a topoisomerase 1 inhibitor that converts replication-associated lesions into actionable DNA damage signals. This article presents a cell-state and repair-capacity framework for interpreting its activity across cancer assays while carefully connecting those principles to new findings on selective CUX2 neuron loss in neuroinflammation.

• Gamma-linolenic Acid: Applied Research Workflows

  2026-09-03

  Build reproducible GLA experiments around lipid handling, LTB4-linked inflammatory assays, viability profiling, and disease-relevant cell models. The workflow also clarifies what can—and cannot—be inferred from new arachidonic acid vaccine-adjuvant findings.

• HRP Goat Anti-Mouse IgG (H+L) Antibody Guide

  2026-09-02

  HRP Goat Anti-Mouse IgG (H+L) Antibody, SKU K1221, provides an HRP-based detection layer for mouse IgG primary antibodies in Western blotting, ELISA, IHC, and ICC. It should not be treated as a universal secondary antibody for other host species, non-IgG mouse immunoglobulins, or fluorescence workflows without separate validation.

• EdU Imaging Kits (Cy3) for Locust Gut Studies

  2026-09-02

  EdU Imaging Kits (Cy3) convert DNA-replication activity into a bright Cy3 signal for microscopy or flow cytometry, enabling direct measurement of proliferating gut cells. The workflow complements RNAi and hormone-rescue experiments in Locusta migratoria by separating effects on S-phase entry from downstream tissue and molting phenotypes.

• Etomoxir A3404 for Reliable Metabolic Assays

  2026-09-01

  Learn how Etomoxir (SKU A3404) can improve interpretation of viability, proliferation, cytotoxicity, and immunometabolic assays by providing a defined CPT-1 perturbation. This scenario-based guide covers concentration selection, solvent handling, whole-blood compatibility, data interpretation, and practical product-selection criteria.

• Irinotecan Workflows for Colorectal Cancer Research

  2026-09-01

  Build more interpretable irinotecan experiments by separating prodrug activation, topoisomerase I–linked DNA damage, and downstream cell death. This workflow guide covers cell-based screening, xenograft translation, assay timing, solubility control, and troubleshooting for reproducible colorectal cancer research.

8466 records 1/565 page Next 12345 下5页 Last page